# Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

> **NCT00764309** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 47 (actual)

## Conditions studied

- Scleroderma

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00764309
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-06
- **Final completion:** 2011-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2012-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00764309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00764309, "Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00764309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*